You are viewing the site in preview mode

Skip to main content

Table 2 Mean PRO scores corresponding to PASDAS and ScoreMDA cutoffs for disease activity

From: Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

PRO* Mean scores (95% CI) corresponding to PASDAS cutoffs for disease activity Mean scores (95% CI) corresponding to MDA
Very low: 1.9 Low: 3.2 High: 5.4 5 points
EQ-5D-3L VAS
 OPAL Broaden 78.2 (76.6, 79.8) 69.5 (68.2, 70.7) 54.7 (53.4, 56.0) 74.6 (73.0, 76.2)
 OPAL Beyond 78.9 (76.7, 81.1) 69.9 (68.2, 71.6) 54.7 (53.2, 56.1) 75.5 (73.2, 77.9)
EQ-5D-3L UI
 OPAL Broaden 0.8 (0.8, 0.8) 0.7 (0.7, 0.7) 0.5 (0.5, 0.6) 0.8 (0.7, 0.8)
 OPAL Beyond 0.8 (0.8, 0.8) 0.7 (0.7, 0.7) 0.5 (0.5, 0.5) 0.8 (0.7, 0.8)
FACIT-F total score
 OPAL Broaden 40.1 (39.2, 41.0) 36.4 (35.6, 37.2) 30.2 (29.4, 31.0) 38.2 (37.3, 39.1)
 OPAL Beyond 40.6 (39.5, 41.7) 36.3 (35.3, 37.2) 29.0 (28.1, 29.8) 39.2 (38.0, 40.4)
FACIT-F ED
 OPAL Broaden 14.3 (14.0, 14.7) 12.7 (12.3, 13.0) 9.9 (9.6, 10.2) 13.4 (13.0, 13.8)
 OPAL Beyond 14.4 (13.9, 15.0) 12.6 (12.2, 13.0) 9.4 (9.0, 9.8) 13.9 (13.4, 14.4)
FACIT-F ID
 OPAL Broaden 25.8 (25.2, 26.3) 23.7 (23.2, 24.2) 20.3 (19.8, 20.8) 24.9 (24.3, 25.4)
 OPAL Beyond 26.2 (25.5, 26.9) 23.7 (23.1, 24.3) 19.6 (19.0, 20.1) 25.4 (24.7, 26.1)
PGJS-VAS, mm
 OPAL Broaden 12.6 (11.1, 14.0) 28.2 (27.1, 29.3) 54.7 (53.6, 55.8) 22.1 (20.4, 23.7)
 OPAL Beyond 11.4 (9.5, 13.3) 27.8 (26.3, 29.2) 55.4 (54.1, 56.7) 20.2 (17.7, 22.7)
PGJS-VAS-PsO, mm
 OPAL Broaden 11.0 (9.1, 12.9) 24.0 (22.4, 25.5) 45.9 (44.2, 47.5) 18.7 (16.7, 20.6)
 OPAL Beyond 8.6 (6.0, 11.2) 22.2 (20.2, 24.2) 45.2 (43.3, 47.0) 16.5 (13.6, 19.5)
SF-36v2 PCS
 OPAL Broaden NA NA NA 45.2 (44.5, 45.8)
 OPAL Beyond NA NA NA 44.6 (43.7, 45.5)
SF-36v2 PF
 OPAL Broaden NA NA NA 45.3 (44.5, 46.1)
 OPAL Beyond NA NA NA 43.4 (42.3, 44.5)
Pain VAS
 OPAL Broaden 13.4 (11.8, 15.0) 26.3 (25.0, 27.5) 48.0 (46.7, 49.4) NA
 OPAL Beyond 11.5 (9.3, 13.8) 25.4 (23.7, 27.1) 48.8 (47.4, 50.3) NA
HAQ-DI
 OPAL Broaden 0.5 (0.4, 0.5) 0.7 (0.6, 0.7) 1.0 (1.0, 1.0) NA
 OPAL Beyond 0.5 (0.4, 0.6) 0.7 (0.7, 0.8) 1.2 (1.1, 1.2) NA
  1. SF-36v2 PCS: norm-based scores were used (a score of 50 representing the mean for the general population, with higher scores indicating less impairment); ScoreMDA: continuous MDA with values from 0 to 7 (0–4, no MDA; 5–7, MDA)
  2. CI confidence interval, ED experience domain, EQ-5D-3L EuroQoL-Five Dimensions-Three Level Health Questionnaire, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, ID impact domain, MDA minimal disease activity, NA not assessed, Pain VAS Patient’s Assessment of Arthritis Pain visual analog scale, PASDAS Psoriatic Arthritis Disease Activity Score, PCS Physical Component Summary, PF physical functioning, PGJS-VAS Patient’s Global Joint and Skin Assessment visual analog scale, PGJS-VAS-PsO PGJS-VAS psoriasis question, PRO patient-reported outcome, SF-36v2 Short Form-36 Health Survey Version 2, acute, VAS visual analog scale
  3. *OPAL Broaden, N = 422; OPAL Beyond, N = 394; all treatment groups from each phase 3 study were pooled for analysis
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us